Phase II Trial of Cladribine and Rituximab for Hairy Cell Leukemia
A phase II trial is investigating the efficacy and safety of cladribine combined with rituximab in hairy cell leukemia patients.
Therapeutic Area
Therapeutic area intelligence for Hairy Cell Leukemia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.